Xiaobing Qian

Title: Innovations by Xiaobing Qian in Pharmaceutical Chemistry

Introduction

Xiaobing Qian is a notable inventor based in Guilford, CT (US). He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds that inhibit Bruton's tyrosine kinase. His work is crucial for advancing treatments for various diseases, including cancer and autoimmune disorders.

Latest Patents

Xiaobing Qian holds a patent for "Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds." This patent describes compounds of Formula I-a and their pharmaceutically acceptable forms. The patent outlines pharmaceutical compositions that contain these compounds, along with methods for treating patients suffering from diseases responsive to tyrosine kinase inhibition. The diseases targeted include cancer, autoimmune diseases, and acute inflammatory reactions. The methods involve administering effective amounts of the compounds to alleviate symptoms or slow disease progression.

Career Highlights

Xiaobing Qian is currently associated with Cgi Pharmaceuticals, Inc., where he continues to innovate in the pharmaceutical sector. His research focuses on developing new therapeutic strategies that leverage the inhibition of Btk activity to improve patient outcomes.

Collaborations

Xiaobing has collaborated with esteemed colleagues such as Kevin S Currie and Robert W DeSimone. These collaborations enhance the research and development efforts at Cgi Pharmaceuticals, Inc., fostering an environment of innovation and discovery.

Conclusion

Xiaobing Qian's contributions to pharmaceutical chemistry, particularly through his patent on Btk inhibitors, highlight his role as a key innovator in the field. His work not only advances scientific knowledge but also has the potential to improve treatment options for patients with serious health conditions.